Defensins play an essential role in innate immunity. In this study, a novel recombinant β-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting β-defensin consists of an EGF-derived oligopeptide (Ec), a β-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the “scaffold” for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cytotoxicity of Ec-LDP-hBD1 to EGFR highly expressed A431 cells was more potent than that to EGFR low-expressed human lung carcinoma A549 and H460 cells (the IC50 values in A431, A549, and H460 cells were 1.8 ± 0.55, 11.9 ± 0.51, and 5.19 ± 1.21 μmol/L, respectively); in addition, the cytotoxicity of Ec-LDP-hBD1 was much stronger than that of Ec-LDP and hBD1. Moreover, Ec-LDP-hBD1 suppressed cancer cell proliferation and induced mitochondria-mediated apoptosis. Its in vivo anticancer action was evaluated in athymic mice with A431 and H460 xenografts. The mice were administered Ec-LDP-hBD1 (5, 10 mg/kg, i.v.) two times with a weekly interval. Administration of Ec-LDP-hBD1 markedly inhibited the tumor growth without significant body weight changes. The in vivo imaging further revealed that Ec-LDP-hBD1 had a tumor-specific distribution with a clear image of localization. The results demonstrate that the novel recombinant EGFR-targeting β-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against relevant cancer cells by inducing mitochondria-mediated apoptosis and exhibits high therapeutic efficacy against the EGFR-expressed carcinoma xenograft. This novel format of β-defensin, which induces mitochondrial-mediated apoptosis, may play an active role in EGFR-targeting cancer therapy.
It is well known that α-defensins are mainly packaged in neutrophil granules (HNP1, HNP2, and HNP3) or secreted by intestinal Paneth cells (human defensin [HD]5 and HD6). HNP1–3 peptides are also secreted, and their accumulation in biological fluids was proposed as a tumor biomarker. It has been reported that α-defensins promote tumor cell growth, but also provoke cell death at higher concentrations. The aim of the present study was to construct a novel fusion protein consisting of oligopeptides specific for human epidermal growth factor receptor (EGFR), lidamycin apoprotein (LDP), and HD5, and investigate its anti-pancreatic cancer activities. HD5 was fused to the Ec-LDP protein to obtain the Ec-LDP-D5 fusion protein by DNA recombination. Then, immunofluorescence and enzyme-linked immunosorbent assays were used to investigate the binding activities of Ec-LDP-D5 to EGFR-overexpressed cancer cells. CCK-8 assay was used to measure Ec-LDP-D5 in vitro cytotoxicity, and AnnexinV-FITC/PI staining assay was used to analyze its apoptosis-inducing efficacy. The Ec-LDP-D5 fusion protein was constructed correctly and expressed in Escherichia coli in insoluble inclusion bodies. The production of Ec-LDP-D5 was 1 mg/L fermentation broth, and the purity of the fusion protein was 85% as analyzed by high-performance liquid chromatography. Ec-LDP-D5 showed strong binding activities for pancreatic cancer cells that highly express EGFR, including PNAC-1 and Aspc-1 cells. The Ec-LDP-D5 fusion protein showed more potent cytotoxicity to cancer cells compared with Ec-LDP. The results from the AnnexinV-FITC/PI staining assay also revealed that Ec-LDP-D5 significantly induced cell apoptosis. The novel Ec-LDP-D5 fusion protein binds to EGFR specifically, and shows potent cytotoxicity and apoptosis-inducing activities towards pancreatic cancer cells, which suggests that it would be a promising cancer therapeutics candidate.